구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PV (Polatuzumab vedotin, Polatuzumab vedotin (PV)) Roche / Genentech·Diffuse Large B-cell Lymphoma 177 trials·t½ 12.2 h |
|---|---|
Overview Program | Polatuzumab vedotin (PV) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | Diffuse Large B-cell Lymphoma |
Overview Indication | Diffuse Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin plus rituximab, cyclophosphamide, doxor |
Technology Linker | linker |
MoA Mechanism | targeting EGFR and CDK receptor |
MoA Biomarker | biomarkers remaining within normal ranges |
PK/PD Half-life | 12.2 h |
PK/PD Species | Mouse, 24 mg/L |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, 24 mg/L |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Heterocycle-Substituted α-Methylene-γ-Butyrolactone Derivatives: Design, Synthesis, and Bioactivity against Phytopathogenic Fungi and Bacteria.. A series of 37 heterocycle-substituted α-methylene-γ-butyrolactone (MBL) derivatives were designed and synthesized. Bioassays showed that these derivatives possessed prominent fungicidal and bactericidal activities against Phytopht… |
Toxicology CRS | Reported |
Clinical Safety signal | Heterocycle-Substituted α-Methylene-γ-Butyrolactone Derivatives: Design, Synthesis, and Bioactivity against Phytopathogenic Fungi and Bacteria.. A series of 37 heterocycle-substituted α-methylene-γ-butyrolactone (MBL) derivatives were designed and synthesized. Bioassays showed that these derivatives possessed prominent fungicidal and bactericidal activities against Phytopht… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100.0% |
Clinical Result source | ClinicalTrials.gov NCT02611323 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02611323 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PV (Polatuzumab vedotin, Polatuzumab vedotin (PV)) Roche / Genentech·Diffuse Large B-cell Lymphoma 177 trials·t½ 12.2 h |
|---|---|
Overview Program | Polatuzumab vedotin (PV) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | Diffuse Large B-cell Lymphoma |
Overview Indication | Diffuse Large B-cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin plus rituximab, cyclophosphamide, doxor |
Technology Linker | linker |
MoA Mechanism | targeting EGFR and CDK receptor |
MoA Biomarker | biomarkers remaining within normal ranges |
PK/PD Half-life | 12.2 h |
PK/PD Species | Mouse, 24 mg/L |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, 24 mg/L |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Heterocycle-Substituted α-Methylene-γ-Butyrolactone Derivatives: Design, Synthesis, and Bioactivity against Phytopathogenic Fungi and Bacteria.. A series of 37 heterocycle-substituted α-methylene-γ-butyrolactone (MBL) derivatives were designed and synthesized. Bioassays showed that these derivatives possessed prominent fungicidal and bactericidal activities against Phytopht… |
Toxicology CRS | Reported |
Clinical Safety signal | Heterocycle-Substituted α-Methylene-γ-Butyrolactone Derivatives: Design, Synthesis, and Bioactivity against Phytopathogenic Fungi and Bacteria.. A series of 37 heterocycle-substituted α-methylene-γ-butyrolactone (MBL) derivatives were designed and synthesized. Bioassays showed that these derivatives possessed prominent fungicidal and bactericidal activities against Phytopht… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100.0% |
Clinical Result source | ClinicalTrials.gov NCT02611323 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02611323 |
추천 비교
추천 비교